CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.

BACKGROUND: There is a paucity of global data on cardiovascular disease (CVD) prevalence in people with type 2 diabetes (T2D). The primary objective of the CAPTURE study was to estimate the prevalence of established CVD and its management in adults with T2D across 13 countries from five continents. Additional objectives were to further characterize the study sample regarding demographics, clinical parameters and medication usage, with particular reference to blood glucose-lowering agents (GLAs: glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors) with demonstrated cardiovascular benefit in randomized intervention trials. METHODS: Data were collected from adults with T2D managed in primary or specialist care in Australia, China, Japan, Czech Republic, France, Hungary, Italy, Argentina, Brazil, Mexico, Israel, Kingdom of Saudi Arabia, and Turkey in 2019, using standardized methodology. CVD prevalence, weighted by diabetes prevalence in each country, was estimated for the overall CAPTURE sample and participating countries. Country-specific odds ratios for CVD prevalence were further adjusted for relevant demographic and clinical parameters. RESULTS: The overall CAPTURE sample included 9823 adults with T2D (n = 4502 from primary care; n = 5321 from specialist care). The overall CAPTURE sample had median (interquartile range) diabetes duration 10.7 years (5.6-17.9 years) and glycated hemoglobin 7.3% (6.6-8.4%) [56 mmol/mol (49-68 mmol/mol)]. Overall weighted CVD and atherosclerotic CVD prevalence estimates were 34.8% (95% confidence interval [CI] 32.7-36.8) and 31.8% (95% CI 29.7-33.8%), respectively. Age, gender, and clinical parameters accounted for some of the between-country variation in CVD prevalence. GLAs with demonstrated cardiovascular benefit were used by 21.9% of participants, which was similar in participants with and without CVD: 21.5% and 22.2%, respectively. CONCLUSIONS: In 2019, approximately one in three adults with T2D in CAPTURE had diagnosed CVD. The low use of GLAs with demonstrated cardiovascular benefit even in participants with established CVD suggested that most were not managed according to contemporary diabetes and cardiology guidelines. Study registration NCT03786406 (registered on December 20, 2018), NCT03811288 (registered on January 18, 2019).

[Cardiovascular effects of new non-insulinic anti-diabetes drugs]. / Efectos cardiovasculares de los nuevos fármacos no insulínicos en diabetes.

Diabetes mellitus is currently a serious public health problem worldwide, that increases the risk of presenting microvascular and macrovascular complications. Although achieving the recommended blood glucose goals reduces the risk of microvascular complications, the effect of the drugs used to treat hyperglycemia on macrovascular complications and cardiovascular death is a cause for concern. In this context, the regulatory agencies have modified the regulations for the approval of new drugs in diabetes, by adding the need to demonstrate that they are capable of lowering blood glucose levels together with a solid assessment of cardiovascular safety. The objective of this study is to review the cardiovascular effects of the new families of non-insulin drugs, with special emphasis on their effect on the risk of major cardiovascular events. In recent years, it has finally been confirmed that some of the drugs used to treat diabetes are not only safe from a cardiovascular point of view, but have even shown capacity to reduce the risk of cardiovascular disease in type 2 diabetes mellitus. The evidence obtained determined the updating of some current therapeutic guidelines when cardiovascular risk should be considered a fundamental variable at the time of therapeutic choice in patients with diabetes.

[Insulinization in type 2 diabetes mellitus. Intensification options]. / Insulinización en la diabetes mellitus tipo 2. Alternativas de intensificación.

Diabetes mellitus is associated with vascular complications and high rates of morbidity and mortality. Timely insulin therapy, intensified when necessary, represent appropriate measures to prevent or delay the onset of complications. However, the incidence of hypoglycemia and difficulties in treatment adherence represent barriers to achieve therapeutic success. Premixes analogs and, specially, combinations of insulin analogues are associated with pharmacokinetic and pharmacodynamic advantages, that translate into clinical benefits such as improved metabolic control, decreased hypoglycemic events and, for their simplicity, potentially greater adherence.

[CAPTURE Study: Argentine results on prevalence of cardiovascular disease in type 2 diabetes mellitus]. / Estudio CAPTURE: Resultados argentinos sobre prevalencia de enfermedad cardiovascular en diabetes mellitus tipo 2.

Cardiovascular disease (CVD) is the main cause of morbidity and mortality in patients with type 2 diabetes mellitus (DM2). However, scarce specific data are available about the prevalence of CVD in that population in daily clinical practice. The CAPTURE study investigated the contemporary prevalence of CVD in a representative sample of DM2 population in 13 countries, distributed over 5 continents (n = 9823). Among the 834 Argentinian participants, the CVD prevalence was 41.5% (n = 347) (95% confidence interval [95%CI]: 38.4-44.7%), while worldwide rate was 34.8% (n = 3582) (95%CI: 32.7-36.8%). In most cases, it was categorized as atherosclerotic CVD 35.3% (n = 295) (95%CI: 32.3; -38.4%). Likewise, the rate of use of antidiabetic drugs with proven cardiovascular benefits was low, both in Argentina (12.8%: n = 107) and global data (21.9%; n = 2151).

La enfermedad cardiovascular (ECV) es la principal causa de morbimortalidad en los pacientes con diabetes mellitus tipo 2 (DM2). Sin embargo, se dispone de escasos datos específicos sobre la prevalencia de ECV en esta población en la práctica clínica cotidiana. El estudio CAPTURE investigó la prevalencia contemporánea de ECV en una muestra representativa de la población con diagnóstico de DM2 en 13 países, distribuidos en 5 continentes (n = 9823). Entre los 834 participantes de Argentina, la prevalencia de ECV fue de 41.5% (n = 347) (intervalo de confianza del 95% [IC95%]: 38.4-44.7%), mientras que a nivel mundial la prevalencia fue 34.8% (n = 3582) (IC95%: 32.7-36.8%). La mayoría de los casos fue categorizada como ECV aterosclerótica: 35.3% (n = 295) (IC95%:32.3-38.4%). Asimismo, la utilización de medicamentos antidiabéticos con beneficios cardiovasculares comprobados fue baja: 12.8% (n = 107) y 21.9% (n = 2151) en Argentina y a nivel global respectivamente.

Methylation of TFAM gene promoter in peripheral white blood cells is associated with insulin resistance in adolescents.

PURPOSE: To explore whether DNA methylation of the mitochondrial transcription factor A (TFAM) promoter is associated with insulin resistance in a sample of adolescents with features of metabolic syndrome. METHODS: The data and blood samples were collected from 122 adolescents out of a cross-sectional study of 934 high-school students. The population was divided into two groups: noninsulin resistance (NIR) and insulin resistance (IR). After bisulfite treatment of genomic DNA from peripheral leukocytes, we used methylation-specific polymerase chain reaction (PCR) to assess DNA methylation of three putative methylation target sites (CpG) in the TFAM promoter. RESULTS: The ratio of the promoter methylated DNA/unmethylated DNA was 0.012+/-0.0009 (1.2% of alleles), and inversely correlated with the biochemical features of insulin resistance (plasma fasting insulin R: -0.26, p<0.004 and homeostasis model assessment (HOMA) index R: -0.27, p<0.002), and obesity (R: -0.27, p<0.002). Multiple regression analysis showed that the log-transformed HOMA index correlated with the status of promoter methylation of TFAM, independently of body mass index (BMI) Z score (beta: -0.33+/-0.094, p=0.00094). Finally, the TFAM promoter methylated DNA/unmethylated DNA ratio was found to be significantly associated with insulin resistance as dichotomous variable (NIR n=45, 0.014+/-0.002 and IR n=77, 0.011+/-0.001, respectively, p<0.016). CONCLUSION: Our findings suggest a potential role of promoter TFAM methylation in the pathogenesis of insulin resistance in adolescents.

¿Cómo individualizar el tratamiento de la hipertensión arterial en las personas con diabetes mellitus tipo 2? / How to individualize arterial hypertension treatment in type 2 diabetes mellitus?

En las personas con diabetes mellitus (DM) e hipertensión arterial (HTA), los objetivos de presión arterial (PA) deben individualizarse considerando el riesgo cardiovascular, los potenciales efectos adversos de los fármacos antihipertensivos, y el costo y las preferencias de los pacientes. En personas con DM y elevado riesgo cardiovascular un objetivo de PA <130/80 mmHg sería apropiado si puede lograrse con seguridad. Si el riesgo cardiovascular es bajo, tratar la HTA con un objetivo <140/90 mmHg. En embarazadas con DM gestacional (DMG) e HTA preexistente, se sugiere un objetivo de PA de 110-135/85 mmHg con la finalidad de reducir el riesgo de eclampsia y minimizar el retraso de crecimiento intrauterino.

In patients with diabetes mellitus (DM) and hypertension (HP), blood pressure (BP) goals should be individualized considering cardiovascular risk, potential adverse effects of antihypertensive medications, cost, and patient preferences. In people with DM and high cardiovascular risk, a BP target <130/80 mmHg would be appropriate if it can be achieved safely. If cardiovascular risk is low, treat hypertension with a target <140/90 mmHg. In pregnant women with gestational diabetes mellitus (GDM) and preexisting hypertension, a BP target of 110-135/85 mmHg is suggested to reduce the risk of eclampsia and minimize intrauterine growth restriction.

¿Cómo individualizar el tratamiento de la hipertensión arterial en las personas con diabetes mellitus tipo 2? / How to individualize arterial hypertension treatment in type 2 diabetes mellitus?

En las personas con diabetes mellitus (DM) e hipertensión arterial (HTA), los objetivos de presión arterial (PA) deben individualizarse considerando el riesgo cardiovascular, los potenciales efectos adversos de los fármacos antihipertensivos, y el costo y las preferencias de los pacientes. En personas con DM y elevado riesgo cardiovascular un objetivo de PA <130/80 mmHg sería apropiado si puede lograrse con seguridad. Si el riesgo cardiovascular es bajo, tartar la HTA con un objetivo <140/90 mmHg. En embarazadas con DM gestacional (DMG) e HTA preexistente, se sugiere un objetivo de PA de 110-135/85 mmHg con la finalidad de reducir el riesgo de eclampsia y minimizar el retraso de crecimiento intrauterino.

In patients with diabetes mellitus (DM) and hypertension (HP), blood pressure (BP) goals should be individualized considering cardiovascular risk, potential adverse effects of antihypertensive medications, cost, and patient preferences. In people with DM and high cardiovascular risk, a BP target <130/80 mmHg would be appropriate if it can be achieved safely. If cardiovascular risk is low, treat hypertension with a target <140/90 mmHg. In pregnant women with gestational diabetes mellitus (GDM) and preexisting hypertension, a BP target of 110-135/85 mmHg is suggested to reduce the risk of eclampsia and minimize intrauterine growth restriction.

Evaluación del estado emocional de personas con diabetes mellitus en la práctica ambulatoria / Evaluation of the emotional state of people with diabetes mellitus in outpatient practice

La aparición de una enfermedad crónica, como la diabetes mellitus (DM), pone a prueba la respuesta del universo físico y psíquico de un individuo. Como objetivo general, se propone evaluar el estado emocional de las personas con DM en la consulta ambulatoria. Como objetivo particular, detectar y monitorear las necesidades psicológicas que deben formar parte integral del cuidado de la DM mediante el uso de métodos validados. El cuestionario WHO-5 se incluye como índice de bienestar general, el PAID-5 revela la existencia de una posible angustia emocional vinculada a la enfermedad, y el PHQ- 9 como índice de depresión. Ante esta situación, el Comité de Aspectos Psicosociales recomienda explorar estos aspectos para optimizar el control y el tratamiento de la enfermedad, proponiendo estas herramientas para que el equipo de salud las emplee en la detección y el reconocimiento del estado emocional de las personas con DM

Occurrence of a chronic disease, such as diabetes, prove the response of the physical and psychic universe of individuals. As a general objective, is proposed to evaluate emotional state of people with diabetes in the outpatient clinic. As principal objective, detection and monitoring the psychological needs should be a main part of diabetes care, using validated tools to evaluate this aspect. WHO-5 questionnaire is included as an index of general well-being, PAID-5, reveals the existence of a possible emotional distress linked to disease, and PHQ-9 is used as an index of depression. At this situation, the Committee on Psycho-Social Aspects recommends explore these psychological aspects, as a way to optimize the control and treatment of disease, and propose the cited tools, to be used by the health team, in detection and recognition of emotional state in people with diabetes.

Evaluación del estado emocional de personas con diabetes mellitus en la práctica ambulatoria / Evaluation of the emotional state of people with diabetes mellitus in outpatient practice

La aparición de una enfermedad crónica, como la diabetes mellitus (DM), pone a prueba la respuesta del universo físico y psíquico de un individuo. Como objetivo general, se propone evaluar el estado emocional de las personas con DM en la consulta ambulatoria. Como objetivo particular, detectar y monitorear las necesidades psicológicas que deben formar parte integral del cuidado de la DM mediante el uso de métodos validados. El cuestionario WHO-5 se incluye como índice de bienestar general, el PAID-5 revela la existencia de una posible angustia emocional vinculada a la enfermedad, y el PHQ-9 como índice de depresión. Ante esta situación, el Comité de Aspectos Psicosociales recomienda explorar estos aspectos para optimizar el control y el tratamiento de la enfermedad, proponiendo estas herramientas para que el equipo de salud las emplee en la detección y el reconocimiento del estado emocional de las personas con DM.

Occurrence of a chronic disease, such as diabetes, prove the response of the physical and psychic universe of individuals. As a general objective, is proposed to evaluate emotional state of people with diabetes in the outpatient clinic. As principal objective, detection and monitoring the psychological needs should be a main part of diabetes care, using validated tools to evaluate this aspect. WHO-5 questionnaire is included as an index of general well-being, PAID-5, reveals the existence of a possible emotional distress linked to disease, and PHQ-9 is used as an index of depression.

Alteraciones electrolíticas y del metabolismo en pacientes con diabetes mellitus y enfermedad renal crónica. Parte 1 / Electrolyte and metabolism alterations in patients with diabetes mellitus and chronic kidney disease. Part 1

En el paciente con diabetes mellitus (DM) y enfermedad renal crónica (ERC), las alteraciones electrolíticas y metabólicas constituyen un verdadero desafío. En noviembre de 2021, el Comité de Nefropatía de la Sociedad Argentina de Diabetes realizó una jornada científica con el objetivo de actualizar las alteraciones hidroelectrolíticas y del metabolismo óseo mineral, y las consideraciones dietarias en ERC y DM.

In patients with diabetes mellitus (DM) and chronic kidney disease (CKD), electrolyte and metabolic alterations constitute a real challenge. In November 2021, the Nephropathy Committee of the Argentine Diabetes Society held a scientific conference with the aim of updating hydroelectrolytic and mineral bone metabolism disorders, and dietary considerations in CKD and DM.

Cardio-metabolic risk factors in Argentine children. A comparative study.

UNLABELLED: Obesity and its complications are emerging in an epidemic manner in Latin American countries. AIMS: To estimate the prevalence of Cardio-Metabolic Risk Factors (CMRFs) and Metabolic Syndrome (MS) in overweight/obese (OW/OB) and normal weight (NW) adolescents and to examine the associated variables. MATERIAL AND METHODS: A cross-sectional comparative study was conducted in two groups of children, between 10 and 19 years of age, in seven Argentine provinces. A survey on dietary habits, physical activity, anthropometric and biochemical data was collected to identify CMRF and MS. The WHO definition adapted to children was used. RESULTS: 1009 children were assessed; 398 were male (39.4%), 601 (59.6%) were NW and 408 (40.4%) were OW/OB. The OW/OB had a significantly higher proportion of values defined as CMRF: 3.7% impaired fasting glucose >110mg/dl; 27.9% insulin >15 or 20µU/l as they were pubertal/prepubertal; 53.2% Homeostatic Model Assessment (HOMA)>2.5; 45.6% High Density Lipoprotein (HDL)<40mg/dl; 37.7% TG>110mg/dl and 13.5% hypertension (SBP and/or diastolic Blood Pressure percentile >90). Prevalence of the MS in OW/OB patients was 40.3%. The MS was not observed in NW children. Significant differences were found for: family history of OW/OB, birth weight (BW), age at menarche, presence of acanthosis nigricans, waist circumference (WC) >90th percentile. The WC was positively correlated with BP, TG, insulin, HOMA and Body mass index Z score and negatively with HDL in the study population. CONCLUSIONS: We confirm obesity as a major determinant of CMRF and MS (40%), especially fat centralization. We stress the need to address obesity prevention plans in children and adolescents.

Jornadas del Comité de Nefropatía de la Sociedad Argentina de Diabetes. Actualización de cirugía bariátrica en paciente con diabetes y enfermedad renal. Parte 2 / Conference of the Nephropathy Committee of the Argentine Diabetes Society. Bariatric surgery update in a patient with diabetes and kidney disease. Part 2

La prevalencia de obesidad y diabetes mellitus se asocia al desarrollo de enfermedad renal crónica y estadios terminales de la misma. En individuos con obesidad se produce un mecanismo de hiperfiltración, probablemente compensatorio para satisfacer la alta demanda metabólica asociada al aumento del peso corporal, con la presencia de proteinuria en individuos sin enfermedad renal. La histopatología muestra una glomeruloesclerosis focal y segmentaria relacionada con la obesidad en un marco de glomerulomegalia. La cirugía metabólica es el medio más efectivo para obtener una pérdida de peso sustancial y persistente. Se ha demostrado la superioridad de la cirugía sobre el tratamiento médico no solo para lograr un mejor control glucémico, sino también para la reducción de los factores de riesgo cardiovascular. Los mecanismos parecen extenderse más allá de la magnitud de la pérdida de peso e incluyen mejoras tanto en los perfiles de incretinas como en la secreción y la sensibilidad a la insulina. El Comité de Nefropatía de la Sociedad Argentina de Diabetes realizó esta revisión sobre los mecanismos involucrados en la obesidad como causa de enfermedad renal o empeoramiento de la misma por diabetes, y los mecanismos a través de los cuales la cirugía bariátrica beneficiaría a los pacientes con diabetes y enfermedad renal crónica en todos los estadios de la misma, así como los controles pre y posquirúrgicos en este tipo de cirugías.

The prevalence of obesity and diabetes mellitus are associated with the development of chronic kidney disease and its terminal stages. In individuals affected by obesity, a probably compensatory hyperfiltration mechanism occurs to satisfy the high metabolic demand associated with increased body weight; it is also associated with the presence and development of proteinuria in individuals without kidney disease. Histopathology shows obesity-related focal and segmental glomerulosclerosis in a setting of glomerulomegaly. Metabolic surgery is the most effective means of obtaining substantial and lasting weight loss. The superiority of surgery over medical treatment has been demonstrated only to achieve better glycemic control, as well as a reduction in cardiovascular risk factors. The mechanisms appear to extend beyond the magnitude of weight loss and include improvements in incretin profiles, insulin secretion, and insulin sensitivity. The Nephropathy Committee of the Argentine Diabetes Society carried out this review on mechanisms involved in obesity as a cause of kidney disease or worsening of kidney disease due to diabetes, the mechanisms by which bariatric surgery would benefit patients with diabetes and kidney disease chronic and its terminal stages, the pre and post-surgical controls that should be performed by patients undergoing this type of surgery

Jornadas del Comité de Nefropatía de la Sociedad Argentina de Diabetes. Actualización de cirugía bariátrica en paciente con diabetes y enfermedad renal. Parte 1 / Conference of the Nephropathy Committee of the Argentine Society of Diabetes. Bariatric surgery update in a patient with diabetes and kidney disease. Part 1

La prevalencia de obesidad y diabetes mellitus se asocia al desarrollo de enfermedad renal crónica y estadios terminales de la misma. En individuos con obesidad, se produce un mecanismo de hiperfiltración, probablemente compensatorio para satisfacer la alta demanda metabólica asociada al aumento del peso corporal, con la presencia de proteinuria, en individuos sin enfermedad renal. La histopatología muestra una glomeruloesclerosis focal y segmentaria relacionada con la obesidad en un marco de glomerulomegalia. La cirugía metabólica es el medio más efectivo para obtener una pérdida de peso sustancial y persistente. Se ha demostrado la superioridad de la cirugía sobre el tratamiento médico no solo para lograr un mejor control glucémico, sino también para la reducción de los factores de riesgo cardiovascular. Los mecanismos parecen extenderse más allá de la magnitud de la pérdida de peso e incluyen mejoras tanto en los perfiles de incretinas como en la secreción y la sensibilidad a la insulina. El Comité de Nefropatía de la Sociedad Argentina de Diabetes realizó esta revisión sobre los mecanismos involucrados en la obesidad como causa de enfermedad renal o empeoramiento de la misma por diabetes, y los mecanismos a través de los cuales la cirugía bariátrica beneficiaría a los pacientes con diabetes y enfermedad renal crónica en todos los estadios de la misma, así como los controles pre y posquirúrgicos en este tipo de cirugías.

The prevalence of obesity and diabetes mellitus are associated with the development of chronic kidney disease and its terminal stages. In individuals affected by obesity, a probably compensatory hyperfiltration mechanism occurs to satisfy the high metabolic demand associated with increased body weight; it is also associated with the presence and development of proteinuria in individuals without kidney disease. Histopathology shows obesity-related focal and segmental glomerulosclerosis in a setting of glomerulomegaly. Metabolic surgery is the most effective means of obtaining substantial and lasting weight loss. The superiority of surgery over medical treatment has been demonstrated only to achieve better glycemic control, as well as a reduction in cardiovascular risk factors. The mechanisms appear to extend beyond the magnitude of weight loss and include improvements in incretin profiles, insulin secretion, and insulin sensitivity. The Nephropathy Committee of the Argentine Diabetes Society carried out this review on mechanisms involved in obesity as a cause of kidney disease or worsening of kidney disease due to diabetes, the mechanisms by which bariatric surgery would benefit patients with diabetes and kidney disease chronic and its terminal stages, the pre and post-surgical controls that should be performed by patients undergoing this type of surgery.

The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with hypertension in adolescents harboring the metabolic syndrome.

BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) has been associated with obesity, obesity-related hypertension, and metabolic syndrome. We investigated the possible contribution of the G-308A TNF-alpha mutant to explain variables of the metabolic syndrome. METHODS: Data and blood samples were used from the 175 adolescents that satisfied the criterion of having systolic or diastolic blood pressures (BP) more than the 80th or less than the 20th percentiles, out of a cross-sectional, population-based study of 934 high school students. Genotyping for the polymorphism was performed by polymerase chain reaction-based restriction fragment length polymorphism analysis. RESULTS: In univariate analysis, we found that there was no difference between A allele carriers and noncarriers in most of the clinical characteristics of the metabolic syndrome such as body mass index (BMI), waist-to-hip ratio, plasma leptin levels, total cholesterol, HDL- and LDL-cholesterol, triglycerides, plasma fasting glucose, insulin, and homocysteine levels. However, we found a significantly (P = .015) higher age- and sex-adjusted systolic BP (Z score) in the A allele carriers, and A allele carriers also showed an elevated homeostasis model assessment of insulin resistance (HOMA) index with respect to noncarriers. Logistic regression analysis indicates that A allele carriers had a 2.8-fold higher probability of being hypertensive independent of BMI, waist-to-hip ratio, and HOMA index. CONCLUSIONS: In this report we found a positive association between the G-308A TNF-alpha variant and systolic arterial BP Z score and HOMA index in adolescents harboring features of metabolic syndrome. Therefore, the A allele may predispose to hypertension and insulin resistance in youth.

Evaluación de la funcionalidad del eje hipotálamo-hipófiso-adrenal a través del test de respuesta del cortisol al despertar en pacientes con diabetes mellitus tipo 1 con y sin depresión: Estudio Multicéntrico Argentino (EMA-1) / Evaluation of the hypothalamo-pituitary-adrenal axis using the cortisol awakening response test in patients with type 1 diabetes mellitus with and without depression: Multicenter Argentine Study (EMA-1)

Introducción: la depresión (DP) tiene una alta prevalencia en pacientes con diabetes mellitus tipo 1 (DM1) y se asocia a repercusiones clínicas negativas como mayor morbimortalidad cardiovascular y complicaciones crónicas. Existen pocos estudios publicados sobre la funcionalidad del eje hipotálamo-hipófiso-adrenal (H-H-A) en DM1 con DP, y la relación entre la DP y el test de respuesta del cortisol al despertar (RCD) con el control glucémico (CG). Objetivos: analizar la funcionalidad del eje H-H-A a través de la evaluación del RCD en pacientes con DM1 (PD1) con y sin DP. Como objetivos secundarios, conocer la prevalencia de DP en PD1 y ver si existe relación entre el RCD y CG, y entre DP y CG. Materiales y métodos: estudio observacional, prospectivo, de corte transversal, multicéntrico, nacional. Se incluyeron PD1 mayores de 18 años; se utilizó cuestionario Patient Health Questionnaire-9 (PHQ-9) para diagnóstico de DP. Se tomaron muestras de cortisol salival al despertar y a los 30 minutos (RCD), y se consideró RCD bloqueado si el valor de cortisol de los 30 minutos no aumentaba más del 50% del basal. Además se tomaron muestras de sangre en ayunas para medir glucemia, fructosamina y HbA1c. Resultados: se incluyeron 79 pacientes, 39% hombres, edad promedio 38±15 años, duración de la diabetes de 16±13 años; 53% casados/en pareja y 87% con ingresos económicos estables. El 68% de los PD1 presentó el RCD bloqueado. En PD1 con DP el 85% presentó el RCD bloqueado vs el 60% en los no deprimidos y dicha diferencia fue marginalmente significativa (p=0,05). La prevalencia de DP fue de 39%. No se encontró ninguna relación significativa entre RCD bloqueado y control glucémico (p>0,05). Los PD1 con DP moderada-severa presentaron un peor control glucémico en relación a los PD1 sin depresión (evaluado por glucemia mayor de 120 mg/dl, fructosamina mayor de 285 umol/l; p<0,05) y la relación no fue significativa para HbA1c aunque mostró una tendencia. Conclusiones: en pacientes con DM1 y DP se halló el RCD bloqueado en un alto porcentaje. Dado que la DP se asocia a mayor morbimortalidad cardiovascular, podría utilizarse el test de RCD como biomarcador de DP, y podría servir para estratificar esta sub-población de alto de riesgo. La depresión moderada-severa se asoció a peor control glucémico, por lo tanto, diagnosticar y tratar adecuadamente la DP en PD1 podría contribuir a prevenir la aparición o progresión de complicaciones crónicas.

Introduction: depression (DP) has a high prevalence in patients with type 1 diabetes mellitus (DM1) and is associated with negative clinicals consequences like more cardiovascular morbimortality and chronic complications. There are few studies published about the dysregulation of hypothalamopituitary-adrenal axis (H-P-A) in DM1 with DP and the relation between DP and the Cortisol Awakening Response Test (CAR) with the glycemic control (GC). Objectives: examine the functionality of the H-P-A axis using the Cortisol Awakening Response Test (CAR), in patients with DM1 (PD1) with and without DP. Determine the prevalence of DP in PD1 and examine if there is any relation between CAR and GC and DP and poorer GC. Materials and methods: observational, prospective, national, multicenter study. Patients with DM1, older than 18 years old; Patient Health-9 questionnaire (PHQ-9) was used to diagnose DP and 2 samples of salivary cortisol, and blood samples for glycemia, glycated albumin and Hba1c. Results: 79 patients with DM1 (PD1) were included, 39% male, mean age 38± 15 years old, an average of 16±13 years evolution of diabetes; 53 % married/couple and 87 % have a regular incomes. 68% of PD1 presented CAR blunted. In PD1 with DP 85% has CAR blunted versus 60% in those without DP, and this difference was marginally significant (p=0.05). The prevalence of DP was 39%. No significant relation was found between CAR blunted and glycemic control (p>0.05).PD1 with Moderate-severe DP showed worse metabolic control than the PD1 without DP (evaluated by glycemia higher than 120 mg/dl, glycated albumin higher than 285 umol/l); p<0.05) and the relation was not significant with HbA1c but it showed a trend. Conclusions: patients with DM1 and DP presented a high prevalence of CAR blunted. DP is related with higher cardiovascular morbi-mortality, thus CAR would be useful as a biomarker of DP and would be used to stratify this population of high risk. DP moderate-severe was related to worse glycemic control, hence diagnose and treat correctly DP in PD1 would contribute to prevent the onset or the evolution of chronic complications.

Type 2 diabetes mellitus management and body mass index: experiences with initiating insulin detemir in the a1chieve study.

INTRODUCTION: This sub-analysis of the A1chieve study aimed to examine the safety and efficacy of insulin detemir (IDet) initiation over 24 weeks in relation to baseline body mass index (BMI) in people with type 2 diabetes mellitus (T2DM). METHODS: A1chieve was a 24-week non-interventional study to assess the safety and efficacy of insulin analogs in routine practice. This sub-analysis included insulin-naïve patients who initiated IDet therapy based on their physicians' decision. Patients were stratified according to baseline BMI (Group I, <25.0 kg/m(2); Group II, 25.0 to <30.0 kg/m(2); Group III, 30.0 to <35.0 kg/m(2); Group IV ≥35.0 kg/m(2)). Safety and efficacy variables were assessed over 24 weeks. RESULTS: Overall, 10,650 insulin-naïve patients were included (3,045 patients in Group I, 4,186 patients in Group II, 2,365 patients in Group III, and 1,054 patients in Group IV). Four serious adverse drug reactions (SADRs) were reported. From baseline to Week 24, there was no statistically significant difference in the proportion of patients reporting overall hypoglycemia in Group I (4.0% vs. 4.4%), while a significant decrease in Group II (4.8% vs. 4.0%, p = 0.0335) and significant increases in Groups III and IV (3.3% vs. 5.4% and 3.4% vs. 7.0%, respectively, p < 0.001) were noted. The mean body weight increased from baseline to Week 24 in Group I (60.7 ± 8.4 vs. 61.8 ± 8.5 kg) and reduced in Groups II, III, and IV (74.5 ± 9.2 vs. 74.2 ± 9.2 kg, 87.4 ± 10.3 vs. 86.0 ± 9.8 kg, and 102.2 ± 14.3 vs. 100.1 ± 14.2 kg, respectively; all p < 0.001). Significant improvements were noted in glycemic parameters, systolic blood pressure, and lipids over 24 weeks, irrespective of baseline BMI status. CONCLUSION: IDet therapy was associated with improved glycemic control and a low number of SADRs. Greater weight loss was observed with higher BMI.

Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.

AIMS: Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve study assessed clinical safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes previously receiving basal-bolus insulin regimens. METHODS: A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart. This sub-analysis assessed patients switching from insulin glargine- or neutral protamine Hagedorn insulin-based basal-bolus insulin regimens to biphasic insulin aspart 30. RESULTS: 1024 patients were included. At 24 weeks, glycated haemoglobin and fasting plasma glucose were significantly reduced from baseline in both cohorts (all p<0.001). The proportion reporting any hypoglycaemia, major hypoglycaemia or nocturnal hypoglycaemia was significantly reduced after 24 weeks (all p<0.05). No serious adverse drug reactions were reported. Both cohorts had significantly improved health-related quality of life (HRQoL; p<0.001). CONCLUSIONS: 24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced. This suggests that people with type 2 diabetes inadequately controlled on basal-bolus insulin regimens can consider biphasic insulin aspart 30.

Manejo de la Hiperuricemia en Pacientes en Argentina. Una Encuesta Mediante Cuestionario / Hyperuricemia Management in Patients from Argentina. A Questionnaire Survey

Resumen Introducción: Durante muchos años el ácido úrico se ha considerado como un producto metabólico inerte del metabolismo de las purinas, sin embargo, ha sido recientemente asociado a una serie de estados de enfermedad crónica. No hay hallazgos concluyentes disponibles en la actualidad para tomar una conducta activa clara respecto al tratamiento de ácido úrico sérico, y cuál sería su objetivo terapéutico. Material y métodos: Debido a esta controversia, se decidió llevar a cabo una encuesta para evaluar cuáles son las decisiones que se toman en este contexto, en el ámbito médico de la Argentina. Se consultó en qué pacientes se evaluaba en forma rutinaria el ácido úrico sérico, resultando en un 53.2% de todos los pacientes, sin diferenciar patologías, y un 11.5% refirió que no lo realiza rutinariamente. Con respecto al tratamiento sólo refirieron tratarlo con enfermedad renal un 62.5%; con diabetes 61.7%; con síndrome metabólico 60.4%; con enfermedad cardiovascular un 50.3%; con gota, cálculos renales o dolor articular, un 91.3%, 74% y 36.1% respectivamente. Resultados: Los datos de la encuesta confirman la falta de evidencia en el criterio para la selección de pacientes, a los fines de evaluar los niveles de ácido úrico sérico y su tratamiento. Conclusiones: De esta forma, se concluye que prima la necesidad de realizar estudios prospectivos y randomizados de las patologías con alta incidencia de uricemia elevada, para poder determinar normativas que orienten una conducta a los especialistas según los resultados obtenidos, y que dicha decisión no esté basada solo en la opinión de los expertos.

Abstract Introduction: For many years, uric acid was considered to be an inert product of purine metabolism; however, it has recently been associated with a number of chronic diseases. Nowadays, there are no conclusive findings available regarding a clear action plan to treat serum uric acid or which specific therapeutic goals it would have. Methods: Given this controversy, a survey was conducted in order to evaluate which decisions are taken regarding this situation within the Argentinian medical community. The question was in which cases serum uric acid was routinely assessed and the result was 53.2% no matter the pathology; 11,5% of physicians did not assess it routinely. Regarding its treatment, 62.5% of them reported to have treated it as part of kidney disease; 61.7 % as part of diabetes; 60.4% as part of metabolic syndrome; 50.3% as part of cardiovascular disease; 91.3 % as part of gout; 74% as part of renal stones, and 36.1% as part of joint pain. Results: The data collected by means of the survey show a lack of evidence for establishing the patient selection criteria when evaluating levels of serum uric acid and its treatment. Conclusions: Therefore, it is concluded that it is necessary to conduct prospective and randomized studies of conditions with a high incidence of elevated uricemia in order to develop guidelines for specialists according to results; this decision should not be based on experts' opinion alone.

Calidad de vida y prestaciones en salud de pacientes con diabetes mellitus tipo 2 según región geográfica en Argentina / Quality of life and health benefits in patients with type 2 diabetes according to geography region in Argentina

Introducción: la adherencia al tratamiento de la diabetes mellitus tipo 2 (DM2) en el adulto es un tema complejo y multifactorial que aúna aspectos propios de la enfermedad como no propios, los cuales impactan en la calidad de vida. En Argentina se presentan grandes dificultades al costear la totalidad del tratamiento de la enfermedad. El impacto del ingreso sobre el gasto en salud en DM2 es mayor para los niveles más bajos de ingresos. Objetivos: analizar en adultos con DM2 en Argentina diferencias en variables de calidad de vida y objetivos metabólicos según regiones geográficas y prestación en salud; conocer el gasto de bolsillo en salud y los costos en salud vinculados a DM2; establecer la asociación entre el gasto de bolsillo con variables socioeconómicas y el cumplimiento de los objetivos metabólicos. Materiales y métodos: sobre ocho regiones geográficas de la República Argentina se incluyeron 1.520 pacientes adultos con DM2 y se los clasificó según prestación en salud (sin prestación, con prestación o jubilados). Se aplicó cuestionario validado autorreferido. Resultados: se encontraron diferencias significativas por región geográfica para jubilación prematura por DM2, pérdida de percepción de calidad de vida y cumplimiento de los objetivos metabólicos. Se encontró significancia estadística del gasto de bolsillo con la presencia de subsidio familiar, la jubilación prematura por DM2 y el cumplimiento de los objetivos metabólicos. Conclusiones: se observó disparidad entre las variables de calidad de vida, el gasto en salud y la percepción de subsidios

Introduction: adherence to treatment of diabetes mellitus type 2 (DT2) in the adult is a complex and multifactorial issue that combines aspects of the disease as not own, which impact on the quality of life. In Argentina there are great difficulties in paying for the entire treatment of the disease. The impact of income on health spending in DT2 is greater for lower income levels. Objectives: to analyze differences in quality of life and metabolic objectives according to geographic regions and health benefits in adults with DT2 in Argentina; know the out of pocket expenses in health and health costs linked to DT2; establish an association between out of pocket spending with socioeconomic variables and compliance with metabolic objectives. Materials and methods: over eight geographic regions of the Argentine Republic, 1.520 adult patients with DT2 were classified according to health benefit (without benefit, with benefits or retirees). Validated self-reported questionnaire was applied. Results: significant differences were found by geographic region for premature retirement due to DT2, the loss of perception of quality of life and the fulfillment of metabolic objectives. Statistical significance of out-of-pocket spending was found with the presence of family allowance, early retirement by DT2 and compliance with metabolic objectives. Conclusions: disparity between the variables of quality of life, health expenditure and perception of subsidies was observed

Adherencia al tratamiento en pacientes con diabetes mellitus tipo 2 en Argentina durante 2015 / Adherence to treatment in patients with type 2 diabetes melltius in Argentina during 2015

Introducción: la interrupción en la adherencia a los tratamientos prescriptos genera obstáculos importantes los cuales impactan negativamente en los indicadores de salud. Objetivos: evaluar la adherencia al tratamiento en pacientes adultos con diabetes mellitus tipo 2 (DM2) en Argentina, y establecer la asociación con el tipo de prestación de atención en salud y la ubicación geográfica. Materiales y métodos: se incluyeron 1.520 individuos pertenecientes a ocho regiones diferentes de la República Argentina durante 2015. Se realizó un estudio transversal. Se aplicó un cuestionario validado autorreferido de opciones múltiples con respuestas policotómicas de puntuación simple. Se empleó una escala cuantitativa y un análisis multivariado de componentes principales. Resultados: la edad media fue de 60,2 años y la antigüedad de DM2 referida correspondió a 10,1 años. La media de HbA1c fue de 7,85%. La media de adherencia general para todas las características fue 4,32 (61,71%). Los resultados de adherencia encontrados se asemejan a otros países en desarrollo a excepción del cuidado de los pies. El factor cuidado de los pies en nuestro país reporta escalas de mayor adherencia. Se detectaron resultados tal vez redundantes como la mayor adherencia al monitoreo en las terapias de uso con insulina, y menores para dieta, ejercicio y solo uso de antidiabéticos orales (ADO), así como también la mayor adherencia en medicación en las terapias con insulina e insulina más ADO. Conclusiones: son alarmantes las bajas escalas referidas al grupo con solo dieta y ejercicio

Introduction: the interruption in the adherence to the prescribed treatments generates important obstacles which negatively impact on health indicators. Objectives: to evaluate adherence to treatment in adult patients with diabetes mellitus type 2 (DT2) in Argentina; associate with the type of health care provision and location. Materials and methods: we included 1.520 individuals belonging to eight different geographical regions of the Argentine Republic during 2015. A cross-sectional study was conducted. A self-reported validated questionnaire of multiple options with simple scoring polycotomic responses was applied. A quantitative scale and a multivariate analysis of main components were applied. Results: the average age was 60.2 years and the seniority of the referred DT2 corresponded to 10.1 years. The average HbA1c was 7.85%. The average general adherence for all characteristics was 4.32 (61.71%). The adherence results found are similar to other developing countries except for the care of the feet. The care factor of the feet in our country report scales of greater adherence. Redundant results are observed, such as greater adherence to monitoring in insulin therapy and less for diet and exercise and only oral antidiabetic drugs (ADO), as well as greater medication adherence in insulin and insulin therapies more ADO. Conclusions: the low scales referred to the group with only diet and exercise are alarming